Download
s13063-021-05168-x.pdf 1,69MB
WeightNameValue
1000 Titel
  • Peritoneal flap for lymphocele prophylaxis following robotic-assisted laparoscopic radical prostatectomy with pelvic lymph node dissection: study protocol and trial update for the randomized controlled PELYCAN study
1000 Autor/in
  1. Neuberger, Manuel |
  2. Kowalewski, K. F. |
  3. Simon, V. |
  4. Wessels, F. |
  5. Siegel, F. |
  6. Worst, T. S. |
  7. Westhoff, N. |
  8. von Hardenberg, J. |
  9. Kriegmair, M. |
  10. Michel, M. S. |
  11. Honeck, P. |
  12. Nuhn, P. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-29
1000 Erschienen in
1000 Quellenangabe
  • 22(1):236
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13063-021-05168-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008541/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Data from interventional studies suggest that a peritoneal flap after pelvic lymph node dissection (LND) during laparoscopic, robotic-assisted radical prostatectomy (RARP) may reduce the rate of symptomatic lymphoceles in transperitoneal approach. However, most of these studies are not conducted in a randomized controlled fashion, thus limiting their scientific value. A recent prospective, randomized, controlled trial (RCT) did not show superiority of a peritoneal flap while further trials are lacking. Therefore, the aim of the presented RCT will be to show that creating a peritoneal flap decreases the rate of symptomatic lymphoceles compared to the current standard procedure without creation of a flap.!##!Methods/design!#!PELYCAN is a parallel-group, patient- and assessor-blinded, phase III, adaptive randomized controlled superiority trial. Men with histologically confirmed prostate cancer who undergo transperitoneal RARP with pelvic LND will be randomly assigned in a 1:1 ratio to two groups-either with creating a peritoneal flap (PELYCAN) or without creating a peritoneal flap (control). Sample size calculation yielded a sample size of 300 with a planned interim analysis after 120 patients, which will be performed by an independent statistician. This provides a possibility for early stopping or sample size recalculation. Patients will be stratified for contributing factors for the development of postoperative lymphoceles. The primary outcome measure will be the rate of symptomatic lymphoceles in both groups within 6 months postoperatively. Patients and assessors will be blinded for the intervention until the end of the follow-up period of 6 months. The surgeon will be informed about the randomization result after performance of vesicourethral anastomosis. Secondary outcome measures include asymptomatic lymphoceles at the time of discharge and within 6 months of follow-up, postoperative complications, mortality, re-admission rate, and quality of life assessed by the EORTC QLQ-C30 questionnaire.!##!Discussion!#!The PELYCAN study is designed to assess whether the application of a peritoneal flap during RARP reduces the rate of symptomatic lymphoceles, as compared with the standard operation technique. In case of superiority of the intervention, this peritoneal flap may be suggested as a new standard of care.!##!Trial registration!#!German Clinical Trials Register DRKS00016794 . Registered on 14 May 2019.
1000 Sacherschließung
lokal Lymphocele
lokal Prostatectomy
lokal Prostatectomy/adverse effects [MeSH]
lokal Urology
lokal Laparoscopy/adverse effects [MeSH]
lokal Randomized controlled trial
lokal Study Protocol
lokal Humans [MeSH]
lokal Lymphocele/diagnosis [MeSH]
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Male [MeSH]
lokal Pelvis [MeSH]
lokal Robotic Surgical Procedures/adverse effects [MeSH]
lokal Lymph Node Excision/adverse effects [MeSH]
lokal Lymphocele/etiology [MeSH]
lokal Lymphocele/prevention
lokal Prostatic Neoplasms/surgery [MeSH]
lokal Robotic surgery
lokal Evidence-based medicine
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-4573-5134|https://frl.publisso.de/adhoc/uri/S293YWxld3NraSwgSy4gRi4=|https://frl.publisso.de/adhoc/uri/U2ltb24sIFYu|https://frl.publisso.de/adhoc/uri/V2Vzc2VscywgRi4=|https://frl.publisso.de/adhoc/uri/U2llZ2VsLCBGLg==|https://frl.publisso.de/adhoc/uri/V29yc3QsIFQuIFMu|https://frl.publisso.de/adhoc/uri/V2VzdGhvZmYsIE4u|https://frl.publisso.de/adhoc/uri/dm9uIEhhcmRlbmJlcmcsIEou|https://frl.publisso.de/adhoc/uri/S3JpZWdtYWlyLCBNLg==|https://frl.publisso.de/adhoc/uri/TWljaGVsLCBNLiBTLg==|https://frl.publisso.de/adhoc/uri/SG9uZWNrLCBQLg==|https://frl.publisso.de/adhoc/uri/TnVobiwgUC4=
1000 Hinweis
  • DeepGreen-ID: e9bdf1fefbc040788c027adb429a0f8b ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465522.rdf
1000 Erstellt am 2023-11-16T14:33:55.404+0100
1000 Erstellt von 322
1000 beschreibt frl:6465522
1000 Zuletzt bearbeitet Fri Dec 01 02:24:06 CET 2023
1000 Objekt bearb. Fri Dec 01 02:24:06 CET 2023
1000 Vgl. frl:6465522
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465522 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source